Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 20/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 20/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 14/20 | 0.86 |
| ▸ | PDE3A | Q14432 | 14/20 | 0.86 |
| ▸ | PDE5A | O76074 | 9/20 | 0.86 |
| ▸ | PDE1A | P54750 | 9/20 | 0.86 |
| ▸ | PDE1B | Q01064 | 9/20 | 0.86 |
| ▸ | PDE1C | Q14123 | 9/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7160159 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7159230 | 0.93 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7159233 | 0.93 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL6441242 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL3805902 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL29357571 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL185627 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL6307929 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7675806 | 0.90 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7673788 | 0.89 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007517820-A | — | — | 2007-07-05 | — | — | JP | claimed |
| EP-1706118-A1 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON A SCOPINEESTER AND NICOTINAMIDE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2006-10-04 | — | — | EP | claimed |
| WO-2005067929-A1 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON A SCOPINEESTER AND NICOTINAMIDE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-28 | — | — | WO | claimed |
| US-20050154006-A1 | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| US-6544983-B2 | Administering 3,4,6,7-tetrahydro-(1,4)diazepino(6,7,1-hi)indol-3-yl)-benzamide or nicotamide or isonicotamide or carboxamide derivatives for treatment of chronic obstructive pulmonary disease | PFIZER INC | 2003-04-08 | — | — | US | claimed |
| US-20020010175-A1 | Diazepinoindoles for the treatment of chronic obstructive pulmonary disease | DOHERTY ANNETTE (FR) | 2002-01-24 | — | — | US | claimed |
| EP-0828742-B1 | DIAZEPINO-INDOLES AS PHOSPHODIESTERASE IV INHIBITORS | JOUVEINAL INST RECH (FR) | 2001-12-19 | — | — | EP | claimed |
| EP-1161950-A1 | Use of diazepinoindoles for the treatment of chronic obstructive pulmonary disease | WARNER-LAMBERT COMPANY (US) | 2001-12-12 | — | — | EP | claimed |
| EP-1161949-A1 | Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease | WARNER-LAMBERT COMPANY (US) | 2001-12-12 | — | — | EP | claimed |
| EP-1132390-A2 | Diazepinoindoles as phophodiesterase inhibitors | INSTITUT DE RECHERCHE JOUVEINAL (FR) | 2001-09-12 | — | — | EP | claimed |
| US-20050154006-A1 | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
| US-6544983-B2 | Administering 3,4,6,7-tetrahydro-(1,4)diazepino(6,7,1-hi)indol-3-yl)-benzamide or nicotamide or isonicotamide or carboxamide derivatives for treatment of chronic obstructive pulmonary disease | PFIZER INC | 2003-04-08 | — | — | US | disclosed |
| US-20020119967-A1 | Pharmaceutical composition for preventing or treating a disease associated with an excess of IL-12-production | WARNER-LAMBERT COMPANY | 2002-08-29 | — | — | US | disclosed |
| US-20020010175-A1 | Diazepinoindoles for the treatment of chronic obstructive pulmonary disease | DOHERTY ANNETTE (FR) | 2002-01-24 | — | — | US | disclosed |
| EP-0828742-B1 | DIAZEPINO-INDOLES AS PHOSPHODIESTERASE IV INHIBITORS | JOUVEINAL INST RECH (FR) | 2001-12-19 | — | — | EP | disclosed |
| EP-1161949-A1 | Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease | WARNER-LAMBERT COMPANY (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1161950-A1 | Use of diazepinoindoles for the treatment of chronic obstructive pulmonary disease | WARNER-LAMBERT COMPANY (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1132390-A2 | Diazepinoindoles as phophodiesterase inhibitors | INSTITUT DE RECHERCHE JOUVEINAL (FR) | 2001-09-12 | — | — | EP | disclosed |
| US-5972927-A | ANTIINFLAMMATORY, ANTIALLERGIC AND BRONCHODILATORY MEDICINAL PRODUCTS, TREATMENT OF ASTHMA | JOUVEINAL (FR) | 1999-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010175-A1 | Diazepinoindoles for the treatment of chronic obstructive pulmonary disease | CYP11B2, CYP11B1, ADRB2 | PDE4A 1163/4885PDE4B 980/4885PDE4C 1806/4885 |
| US-20050154006-A1 | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives | NAMPT, NNT, XDH | PDE4A 701/4885PDE4B 713/4885PDE4C 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.